Search Results - "Soncrant, T T"

The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics by Greig, N. H., De Micheli, E., Holloway, H. W., Yu, Q.-S., Utsuki, T., Perry, T. A., Ingram, D. K., Deutsch, J., Lahiri, D., Soncrant, T. T.

“…Phenserine, a phenylcarbamate of physostigmine, is a new potent and highly selective acetylcholinesterase (AChE) inhibitor, with a >50‐fold activity versus…”
Get full text

Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases by Atack, J R, Yu, Q S, Soncrant, T T, Brossi, A, Rapoport, S I

“…A number of carbamoyl- and N(1)-substituted analogs of physostigmine were synthesized and their in vitro potencies (IC50 values) vs. human erythrocyte and…”
Get more information

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease by Asthana, S, Greig, N H, Holloway, H W, Raffaele, K C, Berardi, A, Schapiro, M B, Rapoport, S I, Soncrant, T T

“…To study the pharmacokinetics and pharmacodynamics of intravenously administered arecoline in subjects with Alzheimer's disease. Plasma arecoline…”
Get more information

Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease by Asthana, S, Greig, N H, Hegedus, L, Holloway, H H, Raffaele, K C, Schapiro, M B, Soncrant, T T

“…To study the pharmacokinetic and pharmacodynamic properties of physostigmine in subjects with Alzheimer's disease. Plasma physostigmine concentration and…”
Get more information

Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease by SONCRANT, T. T, RAFFAELE, K. C, SANJAY ASTHANA, BERARDI, A, MORRIS, P. P, HAXBY, J. V

“…Arecoline, a cholinergic agonist, administered at low doses by continuous intravenous infusion for up to 2 weeks, significantly and replicably improved memory…”
Get full text

Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease by Raffaele, Kathleen C., Asthana, Sanjay, Berardi, Annamaria, Haxby, James V., Morris, P. Pearse, Schapiro, Mark B., Soncrant, Timothy T.

“…Nine patients with possible or probable dementia of the Alzheimer type were tested on nine cognitive tests prior to (two times) and during continuous…”
Get full text

Effect of acute and chronic arecoline treatment on cerebral metabolism and blood flow in the conscious rat by Maiese, K, Holloway, H H, Larson, D M, Soncrant, T T

“…Treatment with the muscarinic agonist arecoline improves memory retention in patients with Alzheimer's disease (AD). In animal models, arecoline selectively…”
Get more information

Adrenalectomy or metyrapone-pretreatment abolishes cerebral metabolic responses to the serotonin agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the hippocampus by Freo, U, Holloway, H W, Kalogeras, K, Rapoport, S I, Soncrant, T T

“…1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a serotonin type 2 (5-HT2) agonist, elevates plasma corticosterone levels and reduces the cerebral…”
Get more information

Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration by Greig, N H, Soncrant, T T, Wozniak, K M, Rapoport, S I

“…The pharmacokinetic distribution of human lymphoblastoid interferon (IFN-alpha), (Wellferon, Burroughs Wellcome Company, Research Triangle Park, NC) in plasma…”
Get more information

Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine by Asthana, S, Raffaele, K C, Berardi, A, Greig, N H, Haxby, J V, Schapiro, M B, Soncrant, T T

“…Physostigmine, a reversible and nonselective cholinesterase inhibitor, administered by steady-state, continuous intravenous infusion to carefully selected…”
Get more information

Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat by Greig, N H, Fredericks, W R, Holloway, H W, Soncrant, T T, Rapoport, S I

“…Pharmacokinetic parameters of human lymphoblastoid interferon (IFN-alpha) delivery to normal rat brain were examined. IFN-alpha concentrations in brain…”
Get more information

Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat by GREIG, N. H, SONCRANT, T. T, SHETTY, H. U, MOMMA, S, SMITH, Q. R, RAPOPORT, S. I

“…Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an…”
Get full text

Cerebral glucose utilization in rats is not altered by hindlimb restraint or by femoral artery and vein cannulation by Soncrant, T T, Holloway, H W, Stipetic, M, Rapoport, S I

“…The effects of immobilization and femoral artery and vein cannulation on resting rates of local cerebral glucose utilization (LCGU) were measured in 35 brain…”
Get more information

Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease by Asthana, Sanjay, Raffaele, Kathleen C., Greig, Nigel H., Berardi, Annamaria, Pearse Morris, P., Schapiro, Mark B., Rapoport, Stanley I., Blackman, Marc R., Soncrant, Timothy T.

“…We have reported that arecoline, a muscarinic receptor agonist replicably enhanced verbal memory in five of nine subjects with Alzheimer's disease (AD). To…”
Get full text

Age-dependent cerebral metabolic effects of unilateral nucleus basalis magnocellularis ablation in rats by De Micheli, E, Soncrant, T T

“…To investigate the age-dependent functional importance of cholinergic neocortical inputs, and to explore whether cortical cholinergic denervation in aged…”
Get more information

Preferential metabolic activation of subcortical brain areas by acute administration of nicotine to rats by McNamara, D, Larson, D M, Rapoport, S I, Soncrant, T T

“…Cerebral metabolic and behavioral effects of acutely administered nicotine were measured in rats in relation to dose. Nicotine 0.1, 1, or 10 mg/kg or vehicle…”
Get more information

Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease by Asthana, S, Raffaele, K C, Greig, N H, Schapiro, M B, Blackman, M R, Soncrant, T T

“…We have reported that physostigmine, a reversible cholinesterase inhibitor, enhances verbal memory in patients with Alzheimer disease (AD). To elucidate the…”
Get more information

Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats by Soncrant, T T, Holloway, H W, Greig, N H, Rapoport, S I

“…In order to determine whether a functional deficit in brain cholinoception accompanies the reported loss of muscarinic receptors with age, local cerebral…”
Get more information

Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders by Kittur, S D, Kittur, D S, Soncrant, T T, Rapoport, S I, Tourtellotte, W W, Nagel, J E, Adler, W H

“…Soluble interleukin-2 (IL-2R) levels in the cerebrospinal fluid (CSF) were studied in infectious, inflammatory, degenerative, and neoplastic disorders to…”
Get more information

Selective changes in local cerebral glucose utilization induced by phenobarbital in the rat by HODES, J.E, SONCRANT, T. T, LARSON, D. M, CARLSSON, S. G, RAPOPORT, S. I

“…Alterations in cerebral metabolic activity were measured after different doses of phenobarbital. Local cerebral glucose utilization was determined in 58 brain…”
Get full text